Pre-Open Movers: Wix Gains on Activist Stake, Take-Two Falls on GTA6 Hack
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
AutoZone (AZO) PT Raised to $2,450 at Jefferies Following Earnings
September 20, 2022 7:47 AM EDTJefferies analyst Bret Jordan raised the price target on AutoZone (NYSE: AZO) to $2,450.00 (from $2,350.00) while maintaining a Buy rating.
The analyst commented, "AZO's Q4'22 comp & EPS of 6.2% & $40.51 beat our ests. (+5.0% & $38.52) and cons. (+3.4% & $38.51) as DIFM was +22.0% y/y while DIY grew 1.1% despite lapping... More
Activist Involvement in Wix.com (WIX) Can Unlock 'Meaningful Value'
September 19, 2022 10:42 AM EDT(Updated - September 19, 2022 10:45 AM EDT)
Shares of Wix.com (NASDAQ: WIX) gained 10% early Monday after activist hedge fund Starboard Value disclosed a 9% stake in the company Friday afternoon and, according to reports from Reuters, spoke to the Israel-based website building platform about improving operations.
Starboard is said to support the company's plans to become profitable and believes it can improve its margins and grow further.... More
Wedbush Stays Sidelined on bluebird bio (BLUE) But Does Sees 'some short-term benefits' for the Company Following Skysona News
September 19, 2022 9:28 AM EDTWedbush analyst David Nierengarten reiterated a Neutral rating and $9.00 price target on bluebird bio (NASDAQ: BLUE).
The analyst comments "While we believe that the approval of SKYSONA is a win for patients suffering from CALD, we see short-term benefits for BLUE. With... More
